Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.17 -0.33 (-0.21%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
15 Best Dividend Stocks for Lifelong Passive Income
These 15 dividend stocks can deliver stable passive income for life. 
Via The Motley Fool
2 Excellent Dividend Stocks to Buy With Less Than $200
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years. 
Via The Motley Fool
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other therapies, demonstrating significant potential in treating relapsed or refractory... 
Via Benzinga
For those who appreciate value investing, NYSE:JNJ is a compelling option with its solid fundamentals.
JOHNSON & JOHNSON (NYSE:JNJ) is an undervalued gem with solid fundamentals. 
Via Chartmill
In-Depth Analysis: Johnson &amp; Johnson Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
The Latest Analyst Ratings For Johnson & Johnson
Via Benzinga
Why Masimo Stock Crushed the Market Today
The company seems to be effecting a smooth transition in its leadership. 
Via The Motley Fool
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
These dividend players could lift your portfolio no matter what the market is doing. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is Johnson & Johnson Stock a Buy?
This healthcare blue chip is making all the right moves to reward shareholders. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Johnson & Johnson
Via Benzinga
Competitor Analysis: Evaluating Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
From Beasley Allen Law Firm
Via Business Wire
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations. 
Via Benzinga
Exposures Product Safety
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
Via Benzinga
Exposures Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
This two-step strategy could set investors up with a large sum of passive income in retirement. 
Via The Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
Via Benzinga
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Should You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
How To Earn $500 A Month From Johnson & Johnson Stock
Johnson & Johnson offers an annual dividend yield of 3.01%. How can investors exploit its dividend yield to pocket a regular $500 monthly? 
Via Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
The FDA is investigating concerns about metals in tampons after a 2024 study. The agency is conducting an internal study and reviewing existing literature to assess potential risks of metal exposure. 
Via Benzinga
Exposures Product Safety
Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
Johnson & Johnson is facing a lawsuit from Associated Production Music for allegedly using unlicensed music in nearly 80 videos, potentially resulting in $12 million in damages under copyright law. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
Johnson & Johnson announced promising Phase 2 SKIPPirr study results for Rybrevant in reducing infusion-related reactions in NSCLC patients. 
Via Benzinga
3 Safe Stocks with Safe Dividends for Your Portfolio
Secure your portfolio with stocks known for their stability and reliable dividend payouts, offering a sense of security during uncertain times. 
Via MarketBeat
Topics Economy
Exposures Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.